Resource: A compendium of HLA types and expression in pediatric cancer models.

Cancer immunotherapy has revolutionized treatment by leveraging the immune system to recognize and destroy tumor cells, offering a promising, less toxic option for pediatric patients. A key component of this response is antigen presentation, which depends on accurate human leukocyte antigen (HLA) typing and expression. However, immune-focused resources for pediatric cancers remain limited. In this study, we present a comprehensive immunogenomic resource covering 231 cancer cell lines and 56 tumor-associated fibroblast cell lines from the Childhood Cancer Model Atlas (CCMA). We inferred high-resolution HLA types, predicted neoantigens arising from somatic single nucleotide variants, gene fusions, and splicing isoforms across multiple tumor types, and quantified HLA expression levels. We also explored immune escape mechanisms, including loss of heterozygosity and allele-specific expression loss of HLA genes. This publicly accessible dataset provides critical insight into the immune landscape of pediatric cancers and serves as a foundational tool for immunotherapy development.